Abingworth, a London, UK-based international investment group dedicated to life sciences, appointed Bali Muralidhar as a Partner based in the London office.
Muralidhar has 15 years professional experience in healthcare across a range of functions including venture investing, R&D, clinical practice and teaching. He will work with the team in the London, Boston and Menlo Park offices to source and evaluate new investment opportunities and support existing venture investments through to exit.
Prior to joining Abingworth, Muralidhar was a senior partner at MVM Partners LLP in London where he completed investments in and served on the boards of several companies, both public and private. Two of these were Wilson Therapeutics and Valneva, both also Abingworth portfolio companies.
Muralidhar obtained a degree in clinical medicine from the University of Oxford and practiced general surgery at the John Radcliffe and Addenbrooke’s Hospitals in Oxford and Cambridge, respectively.
He has a PhD in translational cancer research from the MRC Cancer Cell Unit, University of Cambridge, and has published over a dozen peer reviewed papers,a Bye-Fellow in Medical Sciences at Downing College, Cambridge where he taught pathology, surgery and medicine.
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products having a big impact on health. With over $1.1 billion under management, the firm invests at all stages of development, from startups to publicly traded companies, and across all life science sectors.
Supporting its portfolio companies with a team of 27 at offices in London, Menlo Park (California) and Boston, Abingworth has invested in 152 life science companies, leading to 65 IPOs and 47 mergers and acquisitions.
FinSMEs
26/03/2019